Nanjing Well Pharmaceutical Co Ltd (SHG:603351) — Market Cap & Net Worth
Market Cap & Net Worth: Nanjing Well Pharmaceutical Co Ltd (603351)
Nanjing Well Pharmaceutical Co Ltd (SHG:603351) has a market capitalization of $501.82 Million (CN¥3.43 Billion) as of September 21, 2026. Listed on the SHG stock exchange, this China-based company holds position #12334 globally and #3596 in its home market, demonstrating a 0.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanjing Well Pharmaceutical Co Ltd's stock price CN¥25.32 by its total outstanding shares 135439132 (135.44 Million). Also see 603351 current and non-current assets for a full breakdown of the balance sheet.
Nanjing Well Pharmaceutical Co Ltd Market Cap History: 2019 to 2026
Nanjing Well Pharmaceutical Co Ltd's market capitalization history from 2019 to 2026. Data shows growth from $471.13 Million to $501.82 Million (0.60% CAGR). Also see Nanjing Well Pharmaceutical Co Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Nanjing Well Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanjing Well Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Nanjing Well Pharmaceutical Co Ltd (603351) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.39x
Nanjing Well Pharmaceutical Co Ltd's market cap is 0.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.42x
Nanjing Well Pharmaceutical Co Ltd's market cap is 3.42 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $471.13 Million | $880.76 Million | $128.11 Million | 0.53x | 3.68x |
| 2020 | $434.36 Million | $736.06 Million | $100.45 Million | 0.59x | 4.32x |
| 2021 | $757.58 Million | $1.04 Billion | $101.37 Million | 0.73x | 7.47x |
| 2022 | $424.02 Million | $1.11 Billion | $95.03 Million | 0.38x | 4.46x |
| 2023 | $522.63 Million | $1.16 Billion | $112.20 Million | 0.45x | 4.66x |
| 2024 | $486.75 Million | $1.30 Billion | $146.42 Million | 0.38x | 3.32x |
| 2025 | $515.69 Million | $1.34 Billion | $150.97 Million | 0.39x | 3.42x |
Competitor Companies of 603351 by Market Capitalization
Companies near Nanjing Well Pharmaceutical Co Ltd in the global market cap rankings as of September 21, 2026. Review tangible equity quality of Nanjing Well Pharmaceutical Co Ltd to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nanjing Well Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #612 globally with a market cap of $44.88 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #612 | GALDERMA GROUP AG | NYSE:GALDY | $44.88 Billion | $38.49 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Nanjing Well Pharmaceutical Co Ltd Historical Marketcap From 2019 to 2026
Between 2019 and today, Nanjing Well Pharmaceutical Co Ltd's market cap moved from $471.13 Million to $ 501.82 Million, with a yearly change of 0.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥501.82 Million | -2.69% |
| 2025 | CN¥515.69 Million | +5.94% |
| 2024 | CN¥486.75 Million | -6.86% |
| 2023 | CN¥522.63 Million | +23.26% |
| 2022 | CN¥424.02 Million | -44.03% |
| 2021 | CN¥757.58 Million | +74.41% |
| 2020 | CN¥434.36 Million | -7.81% |
| 2019 | CN¥471.13 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 21st, 2026 the market cap of Nanjing Well Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $501.82 Million USD |
| MoneyControl | $501.82 Million USD |
| MarketWatch | $501.82 Million USD |
| marketcap.company | $501.82 Million USD |
| Reuters | $501.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanjing Well Pharmaceutical Co Ltd
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China and internationally. The company offers excipients for injection, oral, and topical applications; and active pharmaceutical ingredients (API), such as polidocanol and polyethylene glycol 3… Read more